{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T18:33:19Z","timestamp":1793644399029,"version":"4.5.1"},"reference-count":53,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100010544","name":"Exelixis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010544","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA070907"],"award-info":[{"award-number":["CA070907"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015340","name":"Bayer Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015340","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004755","name":"EMD Serono","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004755","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004324","name":"Astellas Pharma US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004224","name":"Peter MacCallum Cancer Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004224","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000156","name":"Fonds de Recherche du Qu\u00e9bec - Sant\u00e9","doi-asserted-by":"publisher","award":["32667"],"award-info":[{"award-number":["32667"]}],"id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020069","name":"Bill and Katie Weaver Charitable Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007723","name":"Takeda Pharmaceuticals U.S.A.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007723","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014931","name":"Arrowhead Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014931","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004628","name":"MedImmune","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004628","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006399","name":"Spectrum Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA016672"],"award-info":[{"award-number":["CA016672"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","award":["K99CA240689"],"award-info":[{"award-number":["K99CA240689"]}],"id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","award":["P30 CA01667"],"award-info":[{"award-number":["P30 CA01667"]}],"id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.annonc.2021.09.021","type":"journal-article","created":{"date-parts":[[2021,10,14]],"date-time":"2021-10-14T01:04:56Z","timestamp":1634173496000},"page":"42-56","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":117,"title":["Distinct tumor-infiltrating lymphocyte landscapes are associated with clinical outcomes in localized non-small-cell lung cancer"],"prefix":"10.1016","volume":"33","author":[{"given":"L.","family":"Federico","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.J.","family":"McGrail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.-E.","family":"Bentebibel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Haymaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Ravelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.-A.","family":"Forget","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Karpinets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Reuben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.V.","family":"Negrao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Khairullah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Weissferdt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.A.","family":"Vaporciyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.B.","family":"Antonoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.-Y.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Futreal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Wistuba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Roth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.A.","family":"Byers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.-O.","family":"Gaudreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Uraoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.F.","family":"Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Dejima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.N.","family":"Lazcano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.M.","family":"Solis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.R.","family":"Parra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.J.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Swisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Cascone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.V.","family":"Heymach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Sepesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.L.","family":"Gibbons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Bernatchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.annonc.2021.09.021_bib1","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.21037\/jtd.2018.03.15","article-title":"Updated statistics of lung and bronchus cancer in United States (2018)","volume":"10","author":"Boloker","year":"2018","journal-title":"J\u00a0Thorac Dis"},{"key":"10.1016\/j.annonc.2021.09.021_bib2","first-page":"7","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.annonc.2021.09.021_bib3","first-page":"87","article-title":"Global cancer statistics, 2012","volume":"65","author":"Torre","year":"2015","journal-title":"CA Cancer J Clin"},{"issue":"suppl 5","key":"10.1016\/j.annonc.2021.09.021_bib4","first-page":"S463","article-title":"The pivotal role of pathology in the management of lung cancer","volume":"5","author":"Davidson","year":"2013","journal-title":"J\u00a0Thorac Dis"},{"key":"10.1016\/j.annonc.2021.09.021_bib5","doi-asserted-by":"crossref","first-page":"5311","DOI":"10.1200\/JCO.2010.28.8126","article-title":"The evolving role of histology in the management of advanced non-small-cell lung cancer","volume":"28","author":"Langer","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2021.09.021_bib6","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.annonc.2021.09.021_bib7","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","article-title":"Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden","volume":"9","author":"Chalmers","year":"2017","journal-title":"Genome Med"},{"key":"10.1016\/j.annonc.2021.09.021_bib8","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/nature10673","article-title":"Cancer immunotherapy comes of age","volume":"480","author":"Mellman","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.annonc.2021.09.021_bib9","doi-asserted-by":"crossref","first-page":"4272","DOI":"10.4049\/jimmunol.168.9.4272","article-title":"Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation","volume":"168","author":"Woo","year":"2002","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.annonc.2021.09.021_bib10","doi-asserted-by":"crossref","first-page":"291","DOI":"10.2217\/imt.11.178","article-title":"Myeloid suppressor cells and immune modulation in lung cancer","volume":"4","author":"Srivastava","year":"2012","journal-title":"Immunotherapy"},{"key":"10.1016\/j.annonc.2021.09.021_bib11","doi-asserted-by":"crossref","first-page":"14381","DOI":"10.1038\/ncomms14381","article-title":"Neutrophils dominate the immune cell composition in non-small cell lung cancer","volume":"8","author":"Kargl","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.annonc.2021.09.021_bib12","article-title":"Neutrophil expansion defines an immunoinhibitory peripheral and intratumoral inflammatory milieu in resected non-small cell lung cancer: a descriptive analysis of a prospectively immunoprofiled cohort","volume":"8","author":"Mitchell","year":"2020","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.annonc.2021.09.021_bib13","doi-asserted-by":"crossref","first-page":"e89014","DOI":"10.1172\/jci.insight.89014","article-title":"Multiparametric profiling of non-small-cell lung cancers reveals distinct immunophenotypes","volume":"1","author":"Lizotte","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.annonc.2021.09.021_bib14","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.cell.2017.04.014","article-title":"Innate immune landscape in early lung adenocarcinoma by paired single-cell analyses","volume":"169","author":"Lavin","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.annonc.2021.09.021_bib15","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1172\/JCI73639","article-title":"PD-1 identifies the patient-specific CD8\u207a tumor-reactive repertoire infiltrating human tumors","volume":"124","author":"Gros","year":"2014","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.annonc.2021.09.021_bib16","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41467-019-14273-0","article-title":"Comprehensive T cell repertoire characterization of non-small cell lung cancer","volume":"11","author":"Reuben","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.annonc.2021.09.021_bib17","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1586\/14737140.2016.1123626","article-title":"Pembrolizumab for the treatment of PD-L1 positive advanced or metastatic non-small cell lung cancer","volume":"16","author":"Dang","year":"2016","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.annonc.2021.09.021_bib18","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"New Engl J Med"},{"key":"10.1016\/j.annonc.2021.09.021_bib19","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1517\/14712598.2016.1145652","article-title":"Pembrolizumab for the treatment of non-small cell lung cancer","volume":"16","author":"Lim","year":"2016","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.annonc.2021.09.021_bib20","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1634\/theoncologist.2015-0498","article-title":"FDA approval summary: pembrolizumab for the treatment of patients with metastatic non-small cell lung cancer whose tumors express programmed death-ligand 1","volume":"21","author":"Sul","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.annonc.2021.09.021_bib21","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2021.09.021_bib22","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus Ipilimumab in advanced non-small-cell lung cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2021.09.021_bib23","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s40425-019-0594-0","article-title":"The promise of Immuno-oncology: implications for defining the value of cancer treatment","volume":"7","author":"Kaufman","year":"2019","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.annonc.2021.09.021_bib24","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2021.09.021_bib25","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2021.09.021_bib26","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1038\/ng.3441","article-title":"Clock-like mutational processes in human somatic cells","volume":"47","author":"Alexandrov","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.annonc.2021.09.021_bib27","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nrg3729","article-title":"Mechanisms underlying mutational signatures in human cancers","volume":"15","author":"Helleday","year":"2014","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.annonc.2021.09.021_bib28","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1101\/gr.219303.116","article-title":"DNA mismatch repair preferentially protects genes from mutation","volume":"28","author":"Belfield","year":"2018","journal-title":"Genome Res"},{"key":"10.1016\/j.annonc.2021.09.021_bib29","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/S1470-2045(17)30516-8","article-title":"Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis","volume":"18","author":"Turajlic","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2021.09.021_bib30","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41540-017-0011-6","article-title":"Improved prediction of PARP inhibitor response and identification of synergizing agents through use of a novel gene expression signature generation algorithm","volume":"3","author":"McGrail","year":"2017","journal-title":"NPJ Syst Biol Appl"},{"key":"10.1016\/j.annonc.2021.09.021_bib31","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/s41586-019-1922-8","article-title":"B\u00a0cells and tertiary lymphoid structures promote immunotherapy response","volume":"577","author":"Helmink","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.annonc.2021.09.021_bib32","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/s41586-019-1906-8","article-title":"B\u00a0cells are associated with survival and immunotherapy response in sarcoma","volume":"577","author":"Petitprez","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.annonc.2021.09.021_bib33","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/s41586-019-1914-8","article-title":"Tertiary lymphoid structures improve immunotherapy and survival in melanoma","volume":"577","author":"Cabrita","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.annonc.2021.09.021_bib34","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1038\/ni.3775","article-title":"Tissue-resident memory features are linked to the magnitude of cytotoxic T cell responses in human lung cancer","volume":"18","author":"Ganesan","year":"2017","journal-title":"Nat Immunol"},{"key":"10.1016\/j.annonc.2021.09.021_bib35","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/s43018-020-0066-y","article-title":"The T cell differentiation landscape is shaped by tumour mutations in lung cancer","volume":"1","author":"Ghorani","year":"2020","journal-title":"Nat Cancer"},{"key":"10.1016\/j.annonc.2021.09.021_bib36","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.cell.2012.08.029","article-title":"Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing","volume":"150","author":"Imielinski","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.annonc.2021.09.021_bib37","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.immuni.2013.10.003","article-title":"Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer","volume":"39","author":"Bindea","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.annonc.2021.09.021_bib38","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1038\/nm.3909","article-title":"The prognostic landscape of genes and infiltrating immune cells across human cancers","volume":"21","author":"Gentles","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.annonc.2021.09.021_bib39","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science (New York, N.Y.)"},{"key":"10.1016\/j.annonc.2021.09.021_bib40","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","article-title":"Genetic basis for clinical response to CTLA-4 blockade in melanoma","volume":"371","author":"Snyder","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2021.09.021_bib41","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1126\/science.aad0095","article-title":"Genomic correlates of response to CTLA-4 blockade in metastatic melanoma","volume":"350","author":"Van Allen","year":"2015","journal-title":"Science (New York, N.Y.)"},{"key":"10.1016\/j.annonc.2021.09.021_bib42","doi-asserted-by":"crossref","first-page":"3475","DOI":"10.4049\/jimmunol.1402711","article-title":"CD8+CD103+ tumor-infiltrating lymphocytes are tumor-specific tissue-resident memory T cells and a prognostic factor for survival in lung cancer patients","volume":"194","author":"Djenidi","year":"2015","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.annonc.2021.09.021_bib43","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1158\/0008-5472.CAN-10-2457","article-title":"Minimal engagement of CD103 on cytotoxic T lymphocytes with an E-cadherin-Fc molecule triggers lytic granule polarization via a phospholipase Cgamma-dependent pathway","volume":"71","author":"Le Floc'h","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.annonc.2021.09.021_bib44","doi-asserted-by":"crossref","first-page":"7072","DOI":"10.1158\/0008-5472.CAN-17-1487","article-title":"Paxillin binding to the cytoplasmic domain of CD103 promotes cell adhesion and effector functions for CD8+ resident memory T cells in tumors","volume":"77","author":"Gauthier","year":"2017","journal-title":"Cancer Res"},{"key":"10.1016\/j.annonc.2021.09.021_bib45","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1038\/s41591-018-0057-z","article-title":"A\u00a0transcriptionally and functionally distinct PD-1(+) CD8(+) T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade","volume":"24","author":"Thommen","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.annonc.2021.09.021_bib46","doi-asserted-by":"crossref","first-page":"4992","DOI":"10.1172\/JCI127967","article-title":"Recognition of human gastrointestinal cancer neoantigens by circulating PD-1+ lymphocytes","volume":"129","author":"Gros","year":"2019","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.annonc.2021.09.021_bib47","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1158\/1078-0432.CCR-17-2156","article-title":"Low PD-1 expression in cytotoxic CD8(+) tumor-infiltrating lymphocytes confers an immune-privileged tissue microenvironment in NSCLC with a prognostic and predictive value","volume":"24","author":"Mazzaschi","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2021.09.021_bib48","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1038\/modpathol.2015.63","article-title":"Clinicopathologic analysis of programmed cell death-1 and programmed cell death-ligand 1 and 2 expressions in pulmonary adenocarcinoma: comparison with histology and driver oncogenic alteration status","volume":"28","author":"Koh","year":"2015","journal-title":"Mod Pathol"},{"key":"10.1016\/j.annonc.2021.09.021_bib49","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1038\/s41590-020-0769-3","article-title":"The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies","volume":"21","author":"Kumagai","year":"2020","journal-title":"Nat Immunol"},{"key":"10.1016\/j.annonc.2021.09.021_bib50","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/s41586-019-1032-7","article-title":"Neoantigen-directed immune escape in lung cancer evolution","volume":"567","author":"Rosenthal","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.annonc.2021.09.021_bib51","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1093\/annonc\/mdw319","article-title":"Prognostic value of tumor-infiltrating lymphocytes differs depending on histological type and smoking habit in completely resected non-small-cell lung cancer","volume":"27","author":"Kinoshita","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2021.09.021_bib52","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1164\/rccm.201309-1611OC","article-title":"Presence of B cells in tertiary lymphoid structures is associated with a protective immunity in patients with lung cancer","volume":"189","author":"Germain","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.annonc.2021.09.021_bib53","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.jtho.2017.03.010","article-title":"Lung adenocarcinoma and squamous cell carcinoma gene expression subtypes demonstrate significant differences in tumor immune landscape","volume":"12","author":"Faruki","year":"2017","journal-title":"J\u00a0Thorac Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753421045191?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753421045191?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T15:35:43Z","timestamp":1778513743000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753421045191"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S0923753421045191"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2021.09.021","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Distinct tumor-infiltrating lymphocyte landscapes are associated with clinical outcomes in localized non-small-cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2021.09.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}]}}